Biology of Gastrointestinal Stromal Tumors -- Corless et al. 22 (18): 3813 -- Journal of Clinical Oncology
|Posted by Administrator (admin) on Apr 06 2006|
|GIST In the News >>|
From the Oregon Health & Science University Cancer Institute, Department of Pathology, and Division of Hematology and Oncology, Oregon Health & Science University and Veterans Affairs Medical Center, Portland, OR; and Department of Pathology, Brigham & Women's Hospital, Boston, MA
Address reprint requests to Michael Heinrich, MD, R&D-19 3710 SW US Veterans Hospital Rd, Portland, OR 97201; e-mail: firstname.lastname@example.org
Once a poorly defined pathologic oddity, in recent years, gastrointestinalstromal tumor (GIST) has emerged as a distinct oncogenetic entitythat is now center stage in clinical trials of kinase-targetedtherapies. This review charts the rapid progress that has establishedGIST as a model for understanding the role of oncogenic kinasemutations in human tumorigenesis. Approximately 80% to 85% ofGISTs harbor activating mutations of the KIT tyrosine kinase.In a series of 322 GISTs (including 140 previously publishedcases) studied by the authors in detail, mutations in the KITgene occurred with decreasing frequency in exons 11 (66.1%),9 (13%), 13 (1.2%), and 17 (0.6%).
Full Text at: http://www.jco.org/cgi/content/abstract/22/18/3813
Last changed: Apr 06 2006 at 6:37 PMBack